Clinical Trials in Baltimore

Showing 20761-20780 of 23,476 trials

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

NCT00079443

This phase I/II trial is studying the best dose of FR901228 when given together with rituximab and fludarabine and to see how well FR901228 works alone in treating patients with relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as FR901228 and fludarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Rituximab may increase the effectiveness of chemotherapy drugs by making cancer cells more sensitive to the drugs.

Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Small Lymphocytic Lymphoma

National Cancer Institute (NCI)60 participantsStarted Jan 2004

Baltimore, Maryland, United States

COMPLETEDPhase 1< 1 mile

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

NCT00009698

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who have undergone bone marrow transplantation for acute myeloid leukemia.

Leukemia

Children's Oncology Group1 participantsStarted Mar 1998

Birmingham, Alabama, United States • Mobile, Alabama, United States • Mobile, Alabama, United States +116 more locations

FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

Find Trials by Condition in Baltimore

A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs

Biodistribution and Dosimetry Evaluation of [124I]FIAU

Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Decitabine in Treating Patients With Myelodysplastic Syndrome

Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors

Assessment of Growth of Infants Fed a New Formula

EMD 121974 in Treating Patients With Progressive or Recurrent Glioma

Methotrexate and Thiotepa in Treating Patients With Newly Diagnosed Primary CNS Lymphoma

Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer

Registration and Informed Consent Study for the Childhood Cancer Research Network

Elemental Formula Hypoallergenicity

Combination Chemotherapy and Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Oligodendroglioma

Interferon Alfa in Treating Patients With Advanced Kidney Cancer

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

A Study to Assess AFM13 in Patients With Hodgkin Lymphoma